Antigen L Proteins Articles & Analysis
12 articles found
Tissue cross-reactivity studies play an essential role in the understanding of immune responses, particularly in the context of autoimmunity, transplant rejection, and vaccine development. These studies aim to identify whether antibodies or T cells generated against a particular antigen react with similar proteins found in different tissues, which can lead to unintended effects and complications. ...
Reduced Immunogenicity PEG masks antigenic epitopes on therapeutic proteins, minimizing antibody-mediated neutralization. This is crucial for biologics like L-asparaginase (Oncaspar®), where PEGylation reduces hypersensitivity reactions in leukemia patients. 3. ...
In recent years, the field of antibody drug design has become increasingly significant in the realm of therapeutic development, driven by the need for more effective and targeted treatments for various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibodies, which are proteins produced by the immune system, have the ability to specifically recognize and bind to ...
Recombinant protein vaccines are vaccines produced using genetic engineering technology. The principle is to clone one or several antigen genes of a pathogen into host cells, causing them to express the corresponding antigen protein. These proteins are then extracted for use in the vaccine. These vaccines can effectively stimulate the immune system to respond to specific pathogens, thereby ...
Recombinant protein vaccines are vaccines prepared by expressing and purifying the antigen proteins of pathogens in engineered cells (such as bacteria, yeast, mammalian cells, and insect cells) using genetic engineering technology. Compared with other types of vaccines, recombinant protein vaccines are more costly but have significantly better safety profiles. The intrinsic fluorescence of a ...
The advent of mRNA vaccines has revolutionized the field of immunization, offering a rapid and adaptable response to emerging infectious diseases. Central to the production of these vaccines are enzymes, which play crucial roles in the synthesis and modification of mRNA molecules. This article delves into the pivotal functions of enzymes in mRNA vaccine manufacturing, highlighting their ...
Recombinant protein vaccine is a type of vaccine that does not contain complete pathogens and is prepared from specific protein antigens produced by heterologous expression systems. Due to their advantages of good safety, strong stability, and relatively low cost, recombinant protein vaccines have been widely favored by researchers in recent years. Currently, recombinant protein vaccines have ...
In recent years, mRNA vaccines have emerged as a revolutionary tool in the fight against infectious diseases, including the ongoing COVID-19 pandemic. These vaccines utilize messenger RNA (mRNA) to instruct cells to produce a protein that triggers an immune response, leading to the production of antibodies that protect against the targeted virus. While mRNA vaccines have shown remarkable efficacy ...
In these computer-based methods, the primary amino acid sequence or 3D structure of antigen proteins from the target pathogen is used as input to analyze the existence of sequences (epitopes) capable of binding to major histocompatibility complex (MHC). In humans, MHC is referred to as human leukocyte antigen (HLA).Assessing Epitope ...
In recent years, PROteolysis TArgeting Chimeras (PROTAC), which utilizes the cell's own degradation mechanisms to eliminate specific disease-related proteins, has emerged as one of the most promising methods. Apart from PROTAC, various targeted protein degradation (TPD) strategies are emerging, involving molecular glue, Autophagy-Targeting Chimera (AUTEC), Autophagosome Tethering Compound ...
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be engineered onto our delivery platform to create effective, multivalent vaccines that are cost-effective and fast to produce. We actively work together with academia and industry to enable the use of our vaccine delivery platform in design and development of new vaccines. Many of these ...
RNA is a hydrophilic, negatively charged macromolecule, and its ability to autonomously transmembrane is limited. Therefore, how to efficiently deliver mRNA to the cytoplasm and play a corresponding role is one of the key issues that limit the application of RNA therapy. The wide range of applications of therapeutic mRNA requires efficient and safe delivery methods. An ideal delivery system ...